$210M Deal Gives Endo Rights to Testosterone Gel Fortesta
By Catherine Hollingsworth
Thursday, August 27, 2009
With an FDA decision drawing near for testosterone gel Fortesta, Endo Pharmaceuticals Inc. has grabbed marketing rights to the hormone replacement therapy in the U.S. under a deal valued at up to $210 million with U.K.-based Prostrakan Group plc. (BioWorld Today)
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.